Jove
Visualize
联系我们

相关概念视频

Preclinical Development: Overview01:28

Preclinical Development: Overview

5.7K
Preclinical development consists of a series of tests that ensure the safety and efficacy of a new therapeutic compound before it is tested in humans. There are four main phases to this process. First, safety pharmacology tests are conducted to ensure the drug does not produce any acutely harmful effects. These tests examine parameters such as bronchoconstriction, cardiac dysrhythmias, blood pressure changes, and ataxia. Next, preliminary toxicological testing is performed to determine the...
5.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.5K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Drug Discovery: Overview01:26

Drug Discovery: Overview

10.9K
Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
10.9K
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

1.1K
Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
1.1K
In Vitro Drug Release Testing: Overview, Development and Validation01:10

In Vitro Drug Release Testing: Overview, Development and Validation

279
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
279
Drug Regulation01:25

Drug Regulation

2.7K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
2.7K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Safeguarding Advanced Therapies-The Dangers of Therapeutic Neuroabandonment: How Should We Ensure Patient Safety and Scientific Integrity When a Commercial Clinical Trial Sponsor Becomes Insolvent?

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Observations on an Open-Label Phase 1/2 Dopamine Gene Therapy Trial (OXB-102/Axo-Lenti-PD) in People with Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

STEM-PD trial protocol: a multi-centre, single-arm, first-in-human, dose-escalation trial, investigating the safety and tolerability of intraputamenal transplantation of human embryonic stem cell-derived dopaminergic cells for Parkinson's disease.

BMJ open·2025
Same author

Uncovering bias and variability in how large language models attribute cardiovascular risk.

Frontiers in digital health·2025
Same author

Clinical trial highlights: Dopamine cell-replacement therapies.

Journal of Parkinson's disease·2025
Same author

Quality-of-Life Outcomes in Adults and Children With Chiari 1 Malformation and in Those Managed Without Surgery: A Prospective, Multicenter, Observational Study.

Neurosurgery·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关实验视频

Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K

药物开发 药物开发

Justine Tin Nok Chan1, Saeed Kayhanian2

  • 1School of Clinical Medicine, University of Cambridge, CB2 0SP, Cambridgeshire, United Kingdom.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 25, 2025
PubMed
概括
此摘要是机器生成的。

阿尔茨海默病 (AD) 抗粉样蛋白试验过度代表白种人,不足代表黑人和西班牙裔参与者. 这种缺乏多样性意味着目前的AD疗法可能不会被证明对所有人群都是安全或有效的.

更多相关视频

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

相关实验视频

Last Updated: Jan 7, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.1K
In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing
08:04

In Vitro Three-Dimensional Sprouting Assay of Angiogenesis Using Mouse Embryonic Stem Cells for Vascular Disease Modeling and Drug Testing

Published on: May 11, 2021

3.3K
Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells
05:45

Developmental Toxicity Assay Based on Real-Time Monitoring of Fibroblast Growth Factor Signal Disruption in Human Induced Pluripotent Stem Cells

Published on: October 10, 2025

451

科学领域:

  • 神经学 神经学
  • 临床试验 临床试验
  • 健康差异 在健康上的差异

背景情况:

  • 阿尔茨海默病 (AD) 的患病率在种族和族群之间存在差异.
  • 第三期临床试验对于确定新的AD疗法的安全性和有效性至关重要.
  • 在试验中准确的人口代表性至关重要,以反映面临风险的人口.

研究的目的:

  • 评估阿尔茨海默病的第三阶段抗粉样蛋白治疗试验中种族群体的人口代表性.
  • 将试验参与者的人口统计数据与美国疾病流行率数据进行比较.

主要方法:

  • 完成的第三阶段抗粉样蛋白单克隆抗体试验对AD的横截面分析.
  • 试验人口统计数据的提取.
  • 将试验数据与美国疾病流行率进行比较,以计算入学发病率比率 (EIR).

主要成果:

  • 分析了19项试验中的18项 (19,613名患者),重点是抗粉样蛋白单克隆抗体.
  • 白人个体的代表过多 (EIR = 1.10),而黑人 (EIR = 0.10) 和西班牙裔 (EIR = 0.66) 个体的代表明显不足.
  • 随着时间的推移,亚洲,黑人或西班牙裔参与者的比例没有显著变化.

结论:

  • 在阿尔茨海默氏症的第三阶段抗粉样蛋白试验中,从历史上看,高加索人群占比过高,黑人和西班牙裔人群占比不足.
  • 目前对AD抗粉样蛋白疗法的证据基础并不成比例地反映疾病的种族和民族人口统计数据.
  • 未来的试验必须优先考虑从代表性不足的群体中积极招募患者,以确保在不同人群中治疗的安全性和有效性.